XL092 and Cemiplimab in BRAF WT Thyroid Cancer

Launched by UNC LINEBERGER COMPREHENSIVE CANCER CENTER · Mar 18, 2025

Keywords

ClinConnect Summary

This clinical trial is investigating a combination of two treatments, XL092 and cemiplimab, to see how safe and effective they are when given before surgery for patients with a specific type of thyroid cancer called anaplastic thyroid cancer (ATC). This trial is aimed at adults aged 18 and older who have tumors that do not have the BRAF V600E mutation, which is a specific genetic change found in some cancers. The study is still in the early phase and has not started recruiting participants yet.

To be eligible for the trial, participants should have a confirmed diagnosis of anaplastic thyroid cancer and be in relatively good health, as indicated by a performance status score of 0-2. This means they should be able to carry out normal activities with minimal issues. Participants will need to agree to provide consent for the study, which includes allowing researchers to use their health information. They should also be willing to undergo biopsies (tissue samples) to help monitor their condition. It's important to note that certain individuals, such as those who are pregnant or have certain autoimmune conditions, may not be able to participate. If you or a loved one is interested in learning more about this trial, please discuss it with a healthcare provider for more personalized information.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Written informed consent was obtained to participate in the study and HIPAA authorization for the release of personal health information.
• • Subjects are willing and able to comply with study procedures based on the judgment of the investigator.
• • Age ≥ 18 years at the time of consent.
• • the Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2.
• • Pathologic findings supporting the clinical impression of anaplastic thyroid cancer. Terminology consistent or suggestive of diagnosis may include the following: anaplastic thyroid carcinoma, undifferentiated carcinoma, squamous carcinoma; carcinoma with spindled, giant cell, or epithelial features; poorly differentiated carcinoma with pleomorphism, extensive necrosis with tumor cells present.
• • Subject is willing to have a fresh biopsy at least 3 days prior to neoadjuvant therapy if archival tissue is unavailable. Also willing to have a biopsy at the time of SOC surgery, if applicable.
• • Must have BRAF V600E mutation-negative tumor, as determined by BRAF V600E immunohistochemistry on tumor tissue or genetic/molecular testing of the tumor.
• Exclusion Criteria:
• • Pregnant or breastfeeding (Note: breast milk cannot be stored for future use while the mother is being treated on the study). Females should not breastfeed while receiving study treatment and for 1 month from the last dose of XL092.
• • Patients who have had prior exposure to any immune modulating agents or any type of small molecule kinase inhibitor (including investigational agents) and have documented disease progression on these agents will not be eligible.
• • Ongoing or recent (within 5 years) evidence of significant autoimmune disease that required treatment with systemic immunosuppressive treatments (i.e., with use of disease modifying agents, corticosteroids (\>10 mg of prednisone or equivalent) or immunosuppressive drugs) which may suggest risk of immune-mediated Adverse Events.
• • Replacement therapy (e.g.: thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment. The following are not exclusionary: vitiligo, childhood asthma that has resolved, type 1 diabetes, residual hypothyroidism that required only hormone replacement, or psoriasis that does not require systemic treatment.
• • Subject history of documented allergic reactions or acute hypersensitivity reactions attributed to antibody treatments.
• • Subject is receiving prohibited medications or treatments as listed in the protocol that cannot be discontinued/replaced by an alternative therapy within 7 days of initiating treatment.
• • Participation in another clinical study with an investigational product during the last 3 weeks.